Caplin Point Laboratories Share Price | Caplin Point Laboratories Stock Screener
CAPLIPOINT
Pharmaceuticals
Share Price NSE
₹2486.60
▲
6.00 (0.24%)
Share Price BSE
₹2487.15
▲
6.20 (0.25%)
As of July 23, 2026, the Caplin Point Laboratories share price (NSE: CAPLIPOINT) is ₹2,486.60 on NSE and ₹2,487.15 on BSE, up 0.24% from the previous close, with shares trading between ₹2,435.40 and ₹2,545.30, and a 52-week range of ₹1,504.80–₹2,671.50.
Analyse CAPLIPOINT share price history and track historical price performance.
Use the Caplin Point Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Caplin Point Laboratories Market Cap
₹20,137.02 Cr.
CAPLIPOINT P/E Ratio (TTM)
30.58
Caplin Point Laboratories P/B Ratio
5.54
EPS (TTM)
₹84.36
Dividend Yield
0.15%
Debt to Equity
-
CAPLIPOINT 52 Week High
₹2671.50
Caplin Point Laboratories 52 Week Low
₹1504.80
Operating Margin
34.00%
Profit Margin
27.50%
CAPLIPOINT Revenue (TTM)
₹629.00
EBITDA
₹233.00
Net Income
₹173.00
Total Assets
₹4,046.00
Total Equity
₹3,586.00
Caplin Point Laboratories Share Price Chart
Screen Caplin Point Laboratories share price with an interactive chart. Analyse CAPLIPOINT price trends and volatility across different timeframes.
Caplin Point Laboratories Company Profile - Fundamental Screener
Screen Caplin Point Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for CAPLIPOINT shares.
Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations,...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
C C Paarthipan
ISIN
INE475E01026
Website
https://www.caplinpoint.net
Caplin Point Laboratories Balance Sheet Screener
Screen CAPLIPOINT balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,046 | 3,208 | 2,698 | 2,191 | 1,736 | 1,364 | 1,126 | 743 | 501 | 358 |
| Current Assets | 2,586 | 2,134 | 1,893 | 1,552 | 1,298 | 1,015 | 823 | 494 | 304 | 179 |
| Fixed Assets | 814 | 546 | 453 | 280 | 287 | 305 | 273 | 227 | 170 | 152 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 29 | 16 | 20 | 16 | 19 | 17 | 25 | 23 | 28 | 20 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 3,586 | 2,886 | 2,347 | 1,907 | 1,510 | 1,203 | 957 | 633 | 364 | 225 |
| Share Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves & Surplus | 3,571 | 2,619 | 2,084 | 1,649 | 1,252 | 954 | 716 | 514 | 349 | 210 |
Caplin Point Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Caplin Point Laboratories income statement and profit fundamentals.
Analyze CAPLIPOINT quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Caplin Point Laboratories share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 629 | 577 | 564 | 533 | 528 | 524 | 504 | 478 | 471 | 453 | 431 | 407 | 401 | 386 | 376 |
| Expenses | 396 | 353 | 345 | 333 | 334 | 331 | 318 | 307 | 308 | 293 | 273 | 269 | 265 | 263 | 254 |
| EBITDA | 233 | 223 | 220 | 201 | 194 | 194 | 185 | 170 | 163 | 160 | 158 | 139 | 135 | 124 | 122 |
| Operating Profit % | 34.00% | 35.00% | 35.00% | 35.00% | 33.00% | 33.00% | 34.00% | 33.00% | 32.00% | 33.00% | 34.00% | 32.00% | 32.00% | 29.00% | 29.00% |
| Depreciation | 19 | 19 | 18 | 16 | 17 | 16 | 17 | 16 | 16 | 14 | 12 | 11 | 11 | 11 | 12 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 213 | 204 | 201 | 185 | 177 | 177 | 169 | 154 | 146 | 145 | 146 | 127 | 124 | 112 | 110 |
| Tax | 41 | 38 | 41 | 34 | 31 | 37 | 38 | 30 | 25 | 26 | 30 | 23 | 23 | 14 | 18 |
| Net Profit | 173 | 166 | 160 | 151 | 145 | 140 | 131 | 125 | 121 | 120 | 116 | 104 | 101 | 97 | 92 |
| EPS | 22.38 | 21.56 | 20.32 | 20.10 | 18.75 | 18.28 | 17.22 | 16.32 | 16.01 | 15.44 | 15.13 | 13.62 | 13.45 | 12.86 | 12.09 |
Caplin Point Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen CAPLIPOINT cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 432 | 318 | 271 | 337 | 269 | 45 | 83 | 67 | 68 | 42 |
| Investing Activities | -333 | -319 | -216 | -377 | -30 | -54 | -100 | -69 | -36 | -6 |
| Financing Activities | -38 | -38 | -28 | -41 | -24 | 80 | 90 | -12 | -7 | -14 |
| Net Cash Flow | 61 | -39 | 27 | -81 | 215 | 70 | 74 | -14 | 25 | 23 |
Caplin Point Laboratories Shareholding Pattern Screener
See Caplin Point Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Caplin Point Laboratories promoter holding and ownership changes for CAPLIPOINT on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.57% | 70.56% | 70.56% | 70.57% | 70.57% | 70.62% | 70.56% | 70.56% |
| FII Holding | 6.15% | 5.73% | 6.17% | 6.51% | 6.59% | 3.34% | 3.37% | 3.70% |
| DII Holding | 2.14% | 2.01% | 2.22% | 2.10% | 2.05% | 1.09% | 1.49% | 1.84% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 14.46% | 15.11% | 14.32% | 14.20% | 14.13% | 17.59% | 17.50% | 17.12% |
| Other Holding | 6.68% | 6.59% | 6.73% | 6.61% | 6.65% | 7.36% | 7.08% | 6.78% |
| Shareholder Count | 93,896 | 96,387 | 94,169 | 93,753 | 93,705 | 81,409 | 80,411 | 96,123 |
Caplin Point Laboratories Share Dividend Screener - Share Yield Analysis
Check Caplin Point Laboratories dividend history with payout and yield data.
View Caplin Point Laboratories dividend details including ex-dates and amounts for CAPLIPOINT stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹6.00 | 0.40% |
| 2024-March | ₹5.00 | 0.25% |
| 2023-March | ₹4.50 | 0.34% |
| 2022-March | ₹4.00 | 0.68% |
| 2021-March | ₹3.00 | 0.44% |
| 2020-March | ₹2.50 | 0.62% |
| 2019-March | ₹2.20 | 0.78% |
| 2018-March | ₹2.00 | 0.50% |
| 2017-March | ₹1.50 | 0.26% |
Caplin Point Laboratories Stock Index Membership
See which indices include Caplin Point Laboratories stock.
Check CAPLIPOINT index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMALLCAP250 QUALITY 50
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
Caplin Point Laboratories Market Events Screener - Corporate Actions
Get Caplin Point Laboratories corporate actions including splits, bonuses, and buybacks.
Check Caplin Point Laboratories stock events that may affect CAPLIPOINT share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-29 | 2026-05-30 | Dividend | ₹ 4.00 /share | 9.85% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 0.09% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 10.93% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | -0.93% |
| 2025-09-22 | 2025-09-22 | Annual General Meeting | NA | 21.42% |
| 2025-09-12 | 2025-09-12 | Dividend | ₹ 3.00 /share | 15.96% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -7.48% |
| 2025-05-30 | 2025-05-30 | Dividend | ₹ 3.00 /share | 7.27% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 8.78% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 7.19% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 12.11% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 23.99% |
| 2024-09-23 | 2024-09-23 | Dividend | ₹ 2.50 /share | 25.81% |
| 2024-05-31 | 2024-05-31 | Dividend | ₹ 2.50 /share | -4.49% |
| 2023-09-14 | 2023-09-14 | Dividend | ₹ 2.50 /share | 5.22% |
Caplin Point Laboratories Competitors Screener - Peer Comparison
Screen CAPLIPOINT competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 469,406 | 40.30 | 61,674 | 12.69% | 11,565 | 62.67 |
| Divis Laboratories | 194,270 | 75.03 | 10,560 | 8.73% | 2,520 | 69.61 |
| Torrent Pharmaceuticals | 190,389 | 75.44 | 13,886 | 20.34% | 2,138 | 53.08 |
| Cipla | 116,459 | 29.67 | 29,045 | 2.24% | 3,870 | 48.42 |
| Zydus Life Science | 115,717 | 22.25 | 27,658 | 17.64% | 5,026 | 59.19 |
| Lupin | 113,700 | 20.85 | 29,039 | 26.75% | 5,356 | 54.70 |
| Mankind Pharma | 105,967 | 53.09 | 14,636 | 14.85% | 1,938 | 50.34 |
| Dr Reddys Laboratories | 102,088 | 24.31 | 35,059 | 3.90% | 4,158 | 31.90 |
| Aurobindo Pharma | 89,736 | 25.44 | 33,385 | 3.21% | 3,376 | 50.49 |
| Laurus Labs | 84,158 | 92.82 | 6,868 | 22.01% | 890 | 59.60 |
Caplin Point Laboratories Company Announcements - News Screener
Screen CAPLIPOINT latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-27 | Closure of Trading Window | - |
| 2026-06-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-14 | Corporate Action-Board approves Dividend | - |
| 2026-05-14 | Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-14 | Board Meeting Outcome for For Meeting Held On May 14 2026 | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-07 | Board Meeting Intimation for Approval Of Financial Results And Declaration Of Interim Dividend If Any Approved By The Board. | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-03-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-03 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-02-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-24 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |